GEVA Key Stats
|Revenue (Quarterly YoY Growth)||-74.78%|
|EPS Diluted (TTM)||-2.994|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-79.90M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-2054%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- Synageva BioPharma™ to Present at Upcoming Investor Conference noodls Dec 4
- Synageva Progresses with Sebelipase Alpha - Analyst Blog Zacks Dec 4
- Synageva BioPharma™ Completes Target Enrollment in Phase 3 ARISE Trial with Sebelipase Alfa in Children and Adults with LAL Deficiency noodls Dec 2
- Synageva (GEVA) Completes Enrollment in Sebelipase Alfa Phase 3; Sees Top-Line Results in H214 Street Insider Dec 2
- Buy Synageva (GEVA) Ahead of P-3 data for Sebelipase; Goldman Starts at Buy Street Insider Nov 15
- Synageva BioPharma™ to Present at the Jefferies 2013 Global Healthcare Conference Business Wire Nov 12
- SYNAGEVA BIOPHARMA CORP Files SEC form 10-Q, Quarterly Report Nov 4
- Synageva BioPharma Breaks Below 200-Day Moving Average - Notable for GEVA Nov 1
- Synageva BioPharma™ Reports Third Quarter 2013 Financial Results noodls Oct 29
- SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E Oct 29
GEVA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Synageva BioPharma is up 29.88% over the last year vs S&P 500 Total Return up 30.90%, Actelion up 63.63%, and Bind Therapeutics up N/A.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for GEVA
Pro Report PDF for GEVA
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download GEVA Pro Report PDF
Pro Strategies Featuring GEVA
Did Synageva BioPharma make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Synageva BioPharma Corp is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need.